A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06130566 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

601

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis Atopic

Interventions

DRUG: Amlitelimab
DRUG: Placebo

Sponsor

Sanofi